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ABSTRACT
Staphylococcus aureus bacteraemia (SAB) is associated with substantial morbidity and mortality
worldwide. The charts of adult patients with SAB who were hospitalised in a Swiss tertiary-care centre
between 1998 and 2002 were studied retrospectively. In total, 308 episodes of SAB were included: 2%
were caused by methicillin-resistant strains; 49% were community-acquired; and 51% were nosocomial.
Bacteraemia without focus was the most common type of community-acquired SAB (52%), whereas
intravenous catheter-related infection predominated (61%) among nosocomial episodes of SAB. An
infectious diseases (ID) specialist was consulted in 82% of all cases; 83% received appropriate antibiotic
treatment within 24 h of obtaining blood cultures. Overall hospital-associated mortality was 20%.
Community-acquired SAB was associated independently with a higher mortality rate than nosocomial
SAB (26% vs. 13%; p 0.009). Independent risk-factors for a fatal outcome were age (p < 0.001),
immunosuppression (p 0.007), alcoholism (p < 0.001), haemodialysis (p 0.03), acute renal failure
(p < 0.001) and septic shock (p < 0.001). Consultation with an ID specialist was associated with a
better outcome in univariate analysis (p < 0.001). Compared with a previous retrospective analysis
performed at the same institution between 1980 and 1986, there was a 140% increase in community-
acquired SAB, a 60% increase in catheter-related SAB, and a 14% reduction in mortality. In conclusion,
mortality in patients with SAB remained high, despite effective antibiotic therapy. Patients with
community-acquired SAB were twice as likely to die as patients with nosocomial SAB. Consultation
with an ID specialist may reduce mortality in patients with SAB.
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INTRODUCTION
Staphylococcus aureus is a leading cause of both
community-acquired and nosocomial bacterae-
mia [1–7]. Among the general population,
25–40% of individuals carry S. aureus in their
anterior nares [8–10], and a substantial propor-
tion of S. aureus bloodstream infections are
endogenous in origin [11]. Of all cases of
S. aureus bacteraemia (SAB), 40–80% are hospi-
tal-acquired [12–20]. In particular, intravenous
catheter-related SAB has emerged as a major
nosocomial infection problem, because of the
increasing use of central venous lines [1,21–24].
A distinctive feature of SAB is the high rate of
bacteraemia without focus among patients with
community-acquired SAB, ranging from 45% to
85% [13,14,25,26]; most cases of nosocomial SAB
have an obvious portal of entry, e.g., intraven-
ous catheters or surgical sites. Endocarditis and
secondary foci are common complications of
SAB, occurring far more frequently in commu-
nity-acquired than in nosocomial SAB [12–14,
25–32], and in patients with bacteraemia with-
out focus than in patients with a known focus
of SAB [13,28–31]. Despite the availability of
effective anti-staphylococcal antibiotics, SAB still
has a mortality rate of 20–40% [12–19,27,33,34].
The emergence of methicillin-resistant S. aureus
(MRSA) has increased further the threat of SAB,
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as MRSA bacteraemia carries a higher risk of
mortality than methicillin-susceptible S. aureus
bacteraemia [14,17,29,35,36]. The prognosis of
SAB can be improved by adequate antibiotic
treatment [35,37] and focus removal [12,19,25],
whereas age, bacteraemia without focus and
septic shock are risk-factors for a fatal outcome
[12–18].
The objective of the present study was to
analyse retrospectively the clinical, microbiolo-
gical and therapeutic features of SAB occurring
at the University Hospital Basel (Switzerland),
with an emphasis on the prognostic impact of
appropriate antibiotic therapy and of consulting
an infectious diseases (ID) specialist. These
results were compared with studies published
previously, and especially with a retrospective
study on SAB performed previously at the same
hospital [13], in order to detect possible changes
in the pattern of staphylococcal disease over
time.
MATERIALS AND METHODS
Setting and study population
The study was performed at the University Hospital Basel,
which is an 800-bed primary- and tertiary-care centre for
adult patients, with 26 000 admissions ⁄ year. Patients with
blood cultures positive for S. aureus who were hospitalised
during the period 1998–2002 were identiﬁed by review of
blood culture results from the bacteriology laboratory. All
patients considered to have true S. aureus bloodstream
infection, deﬁned as at least one blood culture positive for
S. aureus plus a systemic inﬂammatory response syndrome,
were included [38]. Patients with true re-infection could be
included several times. Retrospective data collection
included age, gender, underlying conditions, place of acqui-
sition, primary focus, consultation with an ID specialist,
adequacy and timing of antibiotic treatment, complications,




Vascular disease was deﬁned as coronary heart disease, stroke,
or vascular disease of the extremities. Chronic renal failure was
deﬁned as stable elevation of serum creatinine of > 180 lmol ⁄L.
Immunosuppression included any congenital or acquired
quantitative or qualitative deﬁciency of phagocytic cells,
complement, or humoral or cell-mediated immunity.Neutrope-
nia was deﬁned as an absolute neutrophil count < 500 ⁄lL.
Patients infected with human immunodeﬁciency virus were
considered immunosuppressed at any stage of disease. Im-
munosuppression was also deﬁned as a dose of 25 mg
prednisone ⁄day for > 1 month, or a cumulative dose of
> 700 mg prednisone within 3 months before the onset of SAB.
Place of acquisition and primary focus
SAB was considered to be nosocomial if the ﬁrst positive blood
culture was obtained ‡ 48 h after hospital admission, or
directly following an invasive procedure performed in hospi-
tal, or following haemodialysis. SAB caused by a surgical site
infection was also considered to be nosocomial, even if the
patient was at home when signs and symptoms of sepsis
developed. The primary focus of SAB was determined on the
basis of clinical and radiological manifestations and, whenever
possible, on the isolation of S. aureus from normally sterile sites
other than blood. In addition, intravenous catheter-related SAB
was deﬁned by evidence of inﬂammation at the insertion site
and ⁄or a catheter-tip culture positive for S. aureus, and no
evidence of any other focus. Endocarditis was deﬁned accord-
ing to the modiﬁed Duke criteria [39].
Antibiotic therapy
Appropriate antibiotic treatment was deﬁned as therapy
with at least one antibiotic to which the microorganism was
susceptible, given by an appropriate route and in an
appropriate dosage for a sufﬁcient period of time, according
to well-accepted published guidelines (e.g., The Sanford
Guide to Antimicrobial Therapy [40]). Examples include
therapy for 14 days for SAB caused by intravenous catheter-
related infection, surgical site infection, and skin ⁄ soft tissue
infection, and therapy for 28 days for bacteraemia without
focus or endocarditis. Trimethoprim–sulphamethoxazole,
macrolides, tetracyclines, ﬂuoroquinolone or aminoglycoside
monotherapy, ceftriaxone as deﬁnitive therapy, and ﬂucl-
oxacillin, amoxycillin–clavulanate and ﬁrst- or second-
generation cephalosporins given orally were considered to
be inappropriate regardless of susceptibility. In general, the
antibiotic given as soon as the pathogen was known to be
S. aureus was considered to be the deﬁnitive therapy, as
MRSA is rare in the institution studied. In the few cases
where SAB was caused by MRSA, the antibiotic given as
soon as the susceptibility testing results were known was
considered to be the deﬁnitive therapy.
Complications and outcome
Secondary foci were considered to be either present or absent;
the different kinds of secondary foci were not analysed
separately. Endocarditis was considered to be a separate
entity, not a secondary focus. Acute renal failure was deﬁned
as an increase in baseline serum creatinine of ‡ 20%. Septic
shock was deﬁned according to Bone et al. [38]. Disseminated
intravascular coagulation was diagnosed if the following three
criteria were present (in the absence of other conditions
explaining these ﬁndings): D-dimers > 0.5 mg ⁄L; international
normalised ratio >1.5; and thrombocytes < 100 000 ⁄ lL. No
attempt was made to determine whether in-hospital death was
attributable directly to SAB.
Statistical analysis
Categorical variables were compared using either Pearson’s
chi-square test or Fisher’s exact test, as appropriate. Propor-
tions were compared using the proportions test. Univariate
analysis of risk-factors for mortality was with a binary logistic
regression model. A stepwise logistic regression model was
used to determine the ﬁnal multivariate model. A p value
£ 0.05 was considered signiﬁcant.
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RESULTS
Study population and characteristics of patients
Between January 1998 and December 2002, 2547
episodes of bacteraemia occurred at the Univer-
sity Hospital Basel (20.4 episodes ⁄ 1000 admis-
sions). In total, 341 (13.3%) of these episodes were
caused by S. aureus (2.7 episodes ⁄ 1000 admis-
sions), but a hospital chart was unavailable for 33
patients. The remaining 308 patients all had a
systemic inﬂammatory response syndrome and
thus fulﬁlled the inclusion criteria. The demogra-
phic characteristics and underlying conditions of
these patients are summarised in Table 1. Nota-
bly, 31% of the patients with community-ac-
quired SAB were injecting drug-users. There were
only six (2%) episodes of MRSA bacteraemia.
Place of acquisition, primary focus of SAB and
endocarditis
Of all cases of SAB, 49% were community-
acquired and 51% were nosocomial, most often
acquired on a surgical ward. Bacteraemia without
focus was the most common type of community-
acquired SAB (52%), whereas intravenous cath-
eter-related infection predominated (61%) among
episodes of nosocomial SAB. Endocarditis
accounted for 52 (17%) episodes (Table 2), and
was signiﬁcantly more common in patients with
community-acquired SAB than in patients with
nosocomial SAB (29% vs. 5%; p < 0.001), and also
in patients with bacteraemia without focus than in
patients with a known focus of SAB (36% vs.
10%; p < 0.001; data not shown).
Antibiotic therapy
An ID specialist was consulted in 253 (82%) cases.
Empirical antibiotic therapy was appropriate in
238 (77%) episodes. Deﬁnitive antibiotic therapy
was appropriate in 258 (88%) episodes. Ten
patients died before deﬁnitive therapy could be
initiated, and the type of deﬁnitive therapy was
unknown for ﬁve patients. The most common
empirical therapy was intravenous amoxycillin–
clavulanate (118 (38%) patients, including 48
(16%) patients who also received an aminoglyco-
side). The most common deﬁnitive therapy was
intravenous ﬂucloxacillin (183 (62%) patients,
including 70 (24%) patients who also received
an aminoglycoside).
Timing of antibiotic therapy is shown in
Table 3. The median time between obtaining
blood cultures and starting correct antibiotic
therapy was 3.0 h; 83% of all patients received
appropriate antibiotic treatment within 24 h of
obtaining blood cultures. For 90% of the patients
with community-acquired SAB, blood cultures
were obtained within 6 h of hospital admission.
Complications and outcome of SAB
Complications and outcome of SAB are shown in
Table 4. Secondary foci were signiﬁcantly more
common in patients with community-acquired
SAB than in patients with nosocomial SAB (43%









Median (range) 55 (23–94) 61 (18–92)
Gender, n (%)
Female 55 (37) 48 (30)
Male 95 (63) 110 (70)
Underlying conditions, n (%)a
Vascular disease 45 (30) 58 (37)
Diabetes mellitus 37 (25) 37 (23)
Immunosuppression 29 (19) 41 (26)
Malignancy (not in remission) 17 (11) 36 (23)
Injection drug use 47 (31) 4 (3)
Chronic obstructive pulmonary disease 15 (10) 18 (11)
Congestive heart failure (NYHA III ⁄ IV) 18 (12) 14 (9)
Alcoholism 14 (9) 17 (11)
Chronic hepatic failure (cirrhosis CHILD B ⁄C) 9 (6) 12 (8)
Chronic renal failure without haemodialysis 7 (5) 14 (9)
Chronic renal failure with haemodialysis 4 (3) 11 (7)
aPatients may have more than one underlying condition.
Table 2. Place of acquisition, primary focus and endocar-
ditis in patients with Staphylococcus aureus bacteraemia
Acquisition (n = 308) n (%)
Community-acquired 150 (49)
Nosocomial 158 (51)
Medical ward 54 (18)
Surgical ward 72 (23)
Intensive care unit 32 (10)
Community-
acquired (n = 150)
Nosocomial
(n = 158)
Primary focus, n (%)
Bacteraemia without focus 78 (52) 5 (3)
Skin ⁄ soft tissue infection 45 (30) 4 (2)
Bone ⁄ joint infection 17 (11) 0
Surgical site infection
With foreign body 0 17 (11)
Without foreign body 0 20 (13)
Intravenous catheter-related infection 2 (1)a 96 (61)
Others 8 (5) 16 (10)
Endocarditis, n (%) 44 (29) 8 (5)
On native valve 32 (21) 3 (2)
On artiﬁcial valve 12 (8) 5 (3)
aBoth community-acquired intravenous catheter-related infections were infected
port-a-caths.
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vs. 5%; p < 0.001), and also in patients with
bacteraemia without focus than in patients with a
known focus of SAB (53% vs. 13%; p < 0.001;
data not shown). Common secondary foci were
septic arthritis, spondylodiskitis and skin ⁄ soft-
tissue seeding. The overall hospital mortality rate
was 20%. Patients with community-acquired SAB
had a signiﬁcantly higher mortality rate than
patients with nosocomial SAB (26% vs. 13%;
p 0.009).
Prognostic factors of SAB
Consultation with an ID specialist was associated
in univariate analysis with a better outcome
(p < 0.001), but not in multivariate analysis
(Table 5). No effect of adequacy or timing of
antibiotic therapy on mortality was identiﬁed
(inadequate empirical therapy: OR 1.1,
95% CI 0.5–2.3, p 0.8; inadequate deﬁnitive ther-
apy: OR 0.89, 95% CI 0.8–1.1, p 0.6). Risk-factors
in multivariate analysis for a fatal outcome of SAB
were age, immunosuppression, alcoholism, hae-
modialysis, acute renal failure and septic shock
(Table 5). Endocarditis was not a risk-factor for
mortality (native valve endocarditis: OR 1.4,
95% CI 0.6–3.5, p 0.4; artiﬁcial valve endocarditis:
OR 1.7, 95% CI 0.5–5.6, p 0.4). Nosocomial SAB
was associated independently with a better out-
come (Table 5). The following risk-factors for
mortality (univariate and ⁄ or multivariate
analysis) were signiﬁcantly more frequent for
community-acquired SAB than for nosocomial
SAB: bacteraemia without focus (52% vs.
3%, p < 0.001); secondary foci (43% vs. 5%,
p < 0.001); acute renal failure (29% vs. 16%,
p 0.007); septic shock (13% vs. 7%, p 0.06);
disseminated intravascular coagulation (5% vs.
1%, p 0.03); intensive care unit stay because of
SAB (29% vs. 18%, p 0.05); and mechanical
ventilation because of SAB (9% vs. 4%, p 0.05).
Of the factors associated in univariate analysis
with a better prognosis, intravenous catheter-
related SAB was signiﬁcantly less common among
community-acquired episodes of SAB than among
nosocomial episodes of SAB (1% vs. 61%,
p < 0.001).
DISCUSSION
On comparison of the present study (1998–2002)
with a retrospective study by Lautenschlager et al.
[13] at the same institution during 1980–1986,
there was a 23% increase in SAB since the earlier
study (2.2 vs. 2.7 episodes ⁄ 1000 admissions). The
total rate of bacteraemia also increased from 16.3
to 20.4 episodes ⁄ 1000 admissions, with a stable
percentage of bacteraemia (13%) being caused by
S. aureus. The overall higher frequency of SAB
was related to a 140% rise in community-acquired
SAB (0.5 vs. 1.2 episodes ⁄ 1000 admissions),
whereas the frequency of nosocomial SAB
remained essentially stable (1.2 vs. 1.3 epi-
sodes ⁄ 1000 admissions). In particular, there were
more injecting drug-users with community-ac-
quired SAB in the present study (0.02 vs. 0.4
episodes ⁄ 1000 admissions), reﬂecting an increase
in injecting drug-use in the area and ⁄ or a rise in
infectious complications within this population. It
has been shown previously that infections are the
main reason for hospitalisation of injecting drug-





















Mean, h 10.7 3.6 11.7
Median, h 3.0 (0.5–93.5) 1.5 (0.5–71) 5.5 (1.0–104)
0–6 h, n (%) 170 (66) 129 (90) 81 (58)
6–12 h, n (%) 23 (9) 9 (6) 26 (19)
12–24 h, n (%) 23 (9) 2 (1) 12 (9)
>24 h, n (%) 43 (17) 4 (3) 21 (15)
aData (if available) were analysed for community-acquired and nosocomial SAB.
bData (if available) were analysed for community-acquired SAB and surgical site
infection with signs ⁄ symptoms of sepsis starting at home.








Secondary foci 65 (43) 8 (5)
Acute renal failure 44 (29) 26 (16)
Septic shock 20 (13) 11 (7)
Adult respiratory distress syndrome 6 (4) 3 (2)
Disseminated intravascular coagulation 7 (5) 1 (1)
Intensive care unit (ICU) stay
caused by SAB, n (%)
44 (29) 23 (18;
n = 126a)
Mechanical ventilation caused by SAB, n (%) 14 (9) 6 (4)
Overall in-hospital mortality, n (%) 38 (26b); 21 (13b);
n = 146c n = 156c
Time from ﬁrst positive blood culture to death
Mean, days 8.8 6.6
Median (range), days 6.0 (1–30) 3.5 (1–26)
aPatients who acquired SAB in the ICU (n = 32) were excluded.
bp 0.009; total overall hospital mortality was 20%.
cThe outcome of SAB was unknown for six patients (four community-acquired, two
nosocomial).
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users in this area [41], with one-third being nasal
carriers of S. aureus [42]. Compared with the
study by Lautenschlager et al. [13], there was a
60% increase in intravenous catheter-related SAB
(0.5 vs. 0.8 episodes ⁄ 1000 admissions), and a 14%
reduction in overall in-hospital mortality (34% vs.
20%). Possible explanations for the improved
prognosis include advances in intensive care
treatment during the past two decades, as well
as reduced rates of septic shock, adult respiratory
distress syndrome and disseminated intravascu-
lar coagulation (data not shown), higher rates of
intravenous catheter-related SAB, and increased
availability of an ID specialist consultation service
during the present study period.
A limitation of the present study is the fact
that overall hospital mortality rather than
speciﬁc SAB-related mortality was considered,
thereby leading to a possible overestimation of
the impact of SAB on fatal outcome. However,
this approach was preferred to the bias that
would have been created by trying to determine
retrospectively whether death was attributable
to SAB.
In the present study, signiﬁcant independent
risk-factors for mortality in patients with SAB
were age, immunosuppression, alcoholism, hae-
modialysis, acute renal failure and septic shock.
Additional risk-factors reported in previous stud-
ies are diabetes mellitus, malignancy, chronic
hepatic failure, endocarditis, bacteraemia without
focus, pneumonia as the focus of SAB, non-
eradicable or non-eradicated foci, inadequate
antibiotic therapy, secondary foci and MRSA
bacteraemia [12–19,35–37].
In accordance with published studies
[12,14,25,43], a signiﬁcantly higher mortality rate
was observed in patients with community-
acquired SAB than in patients with nosocomial
SAB (26% vs. 13%). Jensen et al. [12] and Cunney
et al. [14] found mortality rates of 40% and 22%,
respectively, for community-acquired SAB, com-
pared with 29% and 6% for nosocomial SAB. In
the present study, the poorer outcome for
community-acquired SAB may be associated with
the higher frequency of bacteraemia without
focus, secondary foci, acute renal failure, septic
shock, disseminated intravascular coagulation,
intensive care unit stay and mechanical ventila-
tion, all of which were risk-factors for mortality in
univariate and ⁄ or multivariate analysis in
patients with community-acquired SAB. Further-
more, intravenous catheter-related SAB, which
was associated with a better outcome in univari-
ate analysis, was more frequent among episodes
of nosocomial SAB. However, nosocomial SAB
remained associated independently with a better
prognosis following adjustment for these factors,
so that the main reason for the better outcome of
nosocomial SAB is probably associated with the
earlier detection of bloodstream infection in hos-
pital than in the community.
In the present study, consultation with an ID
specialist reduced mortality signiﬁcantly for
patients with SAB according to univariate analy-
sis, despite a possible bias regarding the readiness
to consult an ID specialist, which was probably
greater for critically-ill patients. However, this
result may be biased by a deliberate choice not to
consult an ID specialist for terminally-ill patients,
Table 5. Prognostic factors in




OR (95% CI) p value
Multivariate
analysis
OR (95% CI) p value
Age (10-year increase) 1.3 (1.2–1.6) 0.001 1.05 (1.02–1.07) < 0.001
Immunosuppression 4.1 (1.5–11.3) 0.007
Chronic obstructive pulmonary disease 2.8 (1.2–6.1) 0.01
Congestive heart failure 2.4 (1.0–5.6) 0.05
Alcoholism 4.6 (2.0–10.1) < 0.001 11.7 (3.5–39.7) < 0.001
Chronic hepatic failure 4.5 (1.8–11.6) 0.002
Chronic renal failure with haemodialysis 6.5 (1.2–34.0) 0.03
Nosocomial SAB 0.4 (0.2–0.7) 0.002 0.2 (0.1–0.5) 0.001
Bacteraemia without focus 2.8 (1.5–5.4) 0.001
Surgical site infection without foreign body 0.1 (0.01–1.0) 0.05
Intravenous catheter-related infection 0.1 (0.05–0.4) < 0.001
Infectious diseases specialist consulted 0.3 (0.1–0.5) < 0.001
Secondary foci 1.9 (1.0–3.7) 0.05
Acute renal failure 10.0 (5.1–19.6) < 0.001 4.9 (2.1–11.9) < 0.001
Septic shock 27.7 (10.9–70.4) < 0.001 19.5 (6.2–61.6) < 0.001
Adult respiratory distress syndrome 10.8 (2.6–44.2) 0.001
Disseminated intravascular coagulation 8.7 (2.0–37.7) 0.004
Intensive care unit stay caused by SAB 3.8 (2.0–7.5) < 0.001
Mechanical ventilation caused by SAB 16.3 (5.5–48.3) < 0.001
aOnly variables for which p was signiﬁcant are shown.
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or in cases where patients died before consulta-
tion with an ID specialist was possible. In a
prospective study by Fowler et al. [44], consulta-
tion with an ID specialist increased the cure rate
and decreased the relapse rate signiﬁcantly, but
mortality was not affected. Further prospective
studies are needed to elucidate the inﬂuence of ID
specialists on mortality rates among patients with
SAB and with sepsis in general.
Several prospective studies have shown that
inadequate antibiotic therapy (empirical only,
or empirical and deﬁnitive) is a signiﬁcant
risk-factor for mortality resulting from SAB
[35,37] or from sepsis in general [45–47], with
inadequate therapy being signiﬁcantly more
frequent with MRSA than with methicillin-sus-
ceptible S. aureus bacteraemia [37,46]. In the pre-
sent study, inappropriate treatment had no effect
on the outcome of SAB. This is probably associ-
ated with the fact that most staphylococci at the
institution studied have a wide antibiotic suscep-
tibility range, with MRSA being rare. Therefore,
treatment with antibiotics considered to be
inadequate, despite susceptibility of the isolate,
still had some therapeutic efﬁcacy.
Notably, a delay in correct antibiotic therapy
for >24 h after obtaining blood cultures was not
a risk-factor for a fatal outcome of SAB in the
present study. There are several possible expla-
nations: ﬁrst, the number of patients receiving
delayed correct therapy may have been too
small to detect a statistically signiﬁcant differ-
ence; second, in many cases, delaying correct
therapy meant prescribing inappropriate empir-
ical therapy, which still had some therapeutic
efﬁcacy for the reasons mentioned above; and
third, patients with SAB and a high risk of
death normally appear critically-ill and are
therefore likely to receive earlier antibiotic treat-
ment than patients with SAB in a good general
condition, thus creating a bias. Lodise et al. [34]
conducted a retrospective outcome analysis of
delayed antibiotic treatment for nosocomial
SAB, and reported that a delay in correct
treatment beyond a breakpoint as late as
44.75 h after obtaining blood cultures was an
independent predictor of infection-related mor-
tality. In contrast, a retrospective study by
Fa¨tkenheuer et al. [18] did not detect a signiﬁ-
cant difference in mortality between patients
with SAB whose treatment was started >48 h
after obtaining blood cultures and patients
treated earlier. However, both studies indicated
that some patients with S. aureus infection can
be bacteraemic for several days without their
chances of survival being diminished.
In conclusion, S. aureus remains a common
cause of bloodstream infection, with an increasing
frequency of community-acquired SAB and intra-
venous catheter-related SAB. Despite the availab-
ility of effective anti-staphylococcal drugs and the
advances in intensive care treatment, mortality in
patients with SAB remains high, even at an
institution where MRSA has not (yet) emerged
as an additional threat. Patients with community-
acquired SAB are twice as likely to die as patients
with nosocomial SAB, with between one-quarter
and one-third of patients not surviving until
hospital discharge.
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